Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 1;28(1):27-35.
doi: 10.1158/1078-0432.CCR-21-2639. Epub 2021 Oct 19.

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020

Bhakti Arondekar  1 , Mei Sheng Duh  2 , Rachel H Bhak  2 , Maral DerSarkissian  2   3 , Lynn Huynh  2 , Kelsey Wang  2 , John Wojciehowski  2 , Melody Wu  2 , Bryon Wornson  4 , Alexander Niyazov  5 , George D Demetri  6
Affiliations

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020

Bhakti Arondekar et al. Clin Cancer Res. .

Abstract

Real-world evidence (RWE) has garnered great interest to support registration of new therapies and label expansions by the United States Food and Drug Administration (FDA). Currently, practical insights on the design and analysis of regulatory-grade RWE are lacking. This study aimed to analyze attributes of real-world studies in FDA's decision-making and characteristics of full versus accelerated approvals through a systematic review of oncology product approvals. Oncology approvals from 2015 to 2020 were reviewed from FDA.gov. Applications were screened for inclusion of RWE, and variables related to regulatory designations of the application, pivotal clinical trial, and real-world studies were extracted. FDA feedback was reviewed to identify takeaways and best practices for adequate RWE. Among 133 original and 573 supplemental approvals for oncology, 11 and 2, respectively, included RWE; none predated 2017. All real-world studies were retrospective in nature; the most common data source was chart review, and the most common primary endpoint was overall response rate, as in the pivotal trial. The FDA critiqued the lack of the following: a prespecified study protocol, inclusion/exclusion criteria matching to the trial, comparability of endpoint definitions, methods to minimize confounding and address unmeasured confounding, and plans to handle missing data. All full (versus accelerated) approvals shared the following characteristics: high magnitude of efficacy in the pivotal trial; designations of orphan disease, breakthrough therapy, and priority review; and no advisory committee meeting held. This study found that findings from external control real-world studies complemented efficacy data from single-arm trials in successful oncology product approvals.

PubMed Disclaimer

Figures

Figure 1. Flowchart of oncology new therapy approvals with RWE.
Figure 1.
Flowchart of oncology new therapy approvals with RWE.
Figure 2. Flowchart of oncology supplemental therapy approvals with RWE.
Figure 2.
Flowchart of oncology supplemental therapy approvals with RWE.
See this image and copyright information in PMC

References

    1. US Food and Drug Administration (FDA). Fast Track Designation Requests. 2021[cited 2021 Oct 27]. Available from: https://www.fda.gov/drugs/ind-activity/fast-track-designation-requests.
    1. US Food and Drug Administration (FDA). Use of electronic health record data in clinical investigations—guidance for industry. 2018[cited 2020 Jul 22]. Available from: https://www.fda.gov/media/97567/download.
    1. US Food and Drug Administration (FDA). Frequently Asked Questions: Breakthrough Therapies. 2021[cited 2021 Oct 27]. Available from: https://www.fda.gov/regulatory-information/food-and-drug-administration-....
    1. US Food and Drug Administration (FDA). Best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data. 2013[cited 2020 Jul 22]. Available from: https://www.fda.gov/media/79922/download.
    1. US Food and Drug Administration (FDA). Framework for FDA's real-world evidence program. 2018[cited 2020 Jul 22]. Available from: https://www.fda.gov/media/120060/download.

Publication types

Substances